377 related articles for article (PubMed ID: 28780145)
1. What Is the Role of Chemotherapy in Patients With Chronic Lymphocytic Leukemia?
Cheson BD
Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):723-727. PubMed ID: 28780145
[TBL] [Abstract][Full Text] [Related]
2. Evolving Strategies for the Treatment of Chronic Lymphocytic Leukemia in the Upfront Setting.
Bachow SH; Lamanna N
Curr Hematol Malig Rep; 2016 Feb; 11(1):61-70. PubMed ID: 26951237
[TBL] [Abstract][Full Text] [Related]
3. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment.
Hallek M
Am J Hematol; 2017 Sep; 92(9):946-965. PubMed ID: 28782884
[TBL] [Abstract][Full Text] [Related]
4. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Seymour JF; Kipps TJ; Eichhorst B; Hillmen P; D'Rozario J; Assouline S; Owen C; Gerecitano J; Robak T; De la Serna J; Jaeger U; Cartron G; Montillo M; Humerickhouse R; Punnoose EA; Li Y; Boyer M; Humphrey K; Mobasher M; Kater AP
N Engl J Med; 2018 Mar; 378(12):1107-1120. PubMed ID: 29562156
[TBL] [Abstract][Full Text] [Related]
5. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment.
Hallek M
Am J Hematol; 2015 May; 90(5):446-60. PubMed ID: 25908509
[TBL] [Abstract][Full Text] [Related]
6. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.
Mato AR; Hill BT; Lamanna N; Barr PM; Ujjani CS; Brander DM; Howlett C; Skarbnik AP; Cheson BD; Zent CS; Pu JJ; Kiselev P; Foon K; Lenhart J; Henick Bachow S; Winter AM; Cruz AL; Claxton DF; Goy A; Daniel C; Isaac K; Kennard KH; Timlin C; Fanning M; Gashonia L; Yacur M; Svoboda J; Schuster SJ; Nabhan C
Ann Oncol; 2017 May; 28(5):1050-1056. PubMed ID: 28453705
[TBL] [Abstract][Full Text] [Related]
7. Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia.
Wendtner CM; Gregor M
Leuk Lymphoma; 2018 Feb; 59(2):300-310. PubMed ID: 28565930
[TBL] [Abstract][Full Text] [Related]
8. Prognostic markers and standard management of chronic lymphocytic leukemia.
Stilgenbauer S
Hematology Am Soc Hematol Educ Program; 2015; 2015():368-77. PubMed ID: 26637745
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapies for CLL: Practical issues with the changing treatment paradigm.
Jain N; O'Brien S
Blood Rev; 2016 May; 30(3):233-44. PubMed ID: 26776345
[TBL] [Abstract][Full Text] [Related]
10. Current Treatment of Chronic Lymphocytic Leukemia.
Jamroziak K; Puła B; Walewski J
Curr Treat Options Oncol; 2017 Jan; 18(1):5. PubMed ID: 28185174
[TBL] [Abstract][Full Text] [Related]
11. Expanding the armamentarium for chronic lymphocytic leukemia: A review of novel agents in the management of chronic lymphocytic leukemia.
Marini BL; Samanas L; Perissinotti AJ
J Oncol Pharm Pract; 2017 Oct; 23(7):502-517. PubMed ID: 27357816
[TBL] [Abstract][Full Text] [Related]
12. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment.
Hallek M
Am J Hematol; 2019 Nov; 94(11):1266-1287. PubMed ID: 31364186
[TBL] [Abstract][Full Text] [Related]
13. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
Seymour JF; Ma S; Brander DM; Choi MY; Barrientos J; Davids MS; Anderson MA; Beaven AW; Rosen ST; Tam CS; Prine B; Agarwal SK; Munasinghe W; Zhu M; Lash LL; Desai M; Cerri E; Verdugo M; Kim SY; Humerickhouse RA; Gordon GB; Kipps TJ; Roberts AW
Lancet Oncol; 2017 Feb; 18(2):230-240. PubMed ID: 28089635
[TBL] [Abstract][Full Text] [Related]
14. Targeted Therapies in CLL: Monotherapy Versus Combination Approaches.
Khan M; Siddiqi T
Curr Hematol Malig Rep; 2018 Dec; 13(6):525-533. PubMed ID: 30535947
[TBL] [Abstract][Full Text] [Related]
15. Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG).
Cramer P; Langerbeins P; Eichhorst B; Hallek M
Eur J Haematol; 2016 Jan; 96(1):9-18. PubMed ID: 26332019
[TBL] [Abstract][Full Text] [Related]
16. [Chronic lymphocytic leukemia: current standards and novel approaches].
Tausch E; Stilgenbauer S
Internist (Berl); 2014 Dec; 55(12):1400, 1402-4, 1406-9. PubMed ID: 25392275
[TBL] [Abstract][Full Text] [Related]
17. Approaches for relapsed CLL after chemotherapy-free frontline regimens.
Roeker LE; Mato AR
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):10-17. PubMed ID: 33275712
[TBL] [Abstract][Full Text] [Related]
18. Initial therapy of chronic lymphocytic leukemia.
Eichhorst B; Cramer P; Hallek M
Semin Oncol; 2016 Apr; 43(2):241-50. PubMed ID: 27040702
[TBL] [Abstract][Full Text] [Related]
19. Management of high risk chronic lymphocytic leukaemia (CLL) patients in Australia.
Kuss BJ; Tam CS
Intern Med J; 2017 Dec; 47 Suppl 6():5-10. PubMed ID: 29250930
[TBL] [Abstract][Full Text] [Related]
20. Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy.
Freise KJ; Jones AK; Menon RM; Verdugo ME; Humerickhouse RA; Awni WM; Salem AH
Hematol Oncol; 2017 Dec; 35(4):679-684. PubMed ID: 27982454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]